Crescent Biopharma Announces Grants of Inducement Awards
The employee options carry a $13.94 exercise price and vest subject to continued service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Crescent Biopharma (CBIO) approved inducement options covering 81,525 ordinary shares for six non-executive employees on October 5, 2026.
The independent Compensation Committee approved the awards under the amended 2025 Employment Inducement Incentive Award Plan. The options have a 10-year term and a $13.94 exercise price, matching the Nasdaq closing share price on the approval date. The awards were material to each employee’s acceptance of employment. One-fourth of each award becomes exercisable on the first anniversary of the employee’s start date, followed by one-forty-eighth monthly, subject to continuous service through each vesting date.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 81,525 ordinary shares at $13.94 per share create potential dilution upon exercise.
Key Figures
- Options granted
- 81,525 shares
- Aggregate awards to six non-executive employees
- Exercise price
- $13.94 per share
- Equal to the October 5, 2026 closing price
- Option term
- 10 years
- Inducement options
- Initial vesting
- One-fourth of shares
- On the first anniversary of each employee’s start date, subject to continuous service
- Subsequent vesting
- One-forty-eighth of shares monthly
- After initial vesting, subject to continuous service
Historical Context
-
Options for 31,200 shares to two employees, with a 10-year term and $14.24 exercise price.
-
Options for 58,650 shares to two employees, with a 10-year term and $20.46 exercise price.
-
Options for 19,425 shares to one employee, with a 10-year term and $14.47 exercise price.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 81,525 shares of the Company’s ordinary shares to six non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on October 5, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options were granted with a 10-year term and an exercise price equal to
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Contacts
Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of Crescent Biopharma’s employee inducement options?
The awards cover 81,525 ordinary shares for six non-executive employees, with a $13.94 exercise price and a 10-year term. One-fourth vests on the first anniversary of each employee’s start date, followed by one-forty-eighth monthly thereafter, subject to continuous service through the applicable vesting dates.